Pfizer, along with Alliance Foundation Trials (AFT) and six other international cancer research groups, has commenced a phase 3 clinical study to assess palbociclib (Ibrance) for the treatment of patients with metastatic breast cancer.

Ibrance is an oral inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), which triggers cellular progression.

Patina is a randomized, open-label and phase 3 clinical trial, which will assess palbociclib in combination with anti-HER2 therapy and endocrine therapy against standard therapy as a first-line treatment for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer.

In the US, Ibrance secured approval to treat HR+ and HER2-negative (HER2-) advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or fulvestrant in women with disease progression following…

Pin It on Pinterest

Share This